Group Effect in bioequivalence study [General Sta­tis­tics]

posted by pash413 – India, 2011-07-30 17:50 (5437 d 01:43 ago) – Posting: # 7241
Views: 11,138

Dear All,


We are conducting bioequivalence studies on patients, carried out at different clinical sites. As the biostudies are conducted on cancer patients, the dosing is planned [either single (one) or in group] at different clinical sites based on the availability of patients. Even at the same clinical site the dosing is done for different group which is separated by 1- 3 months.

As per FDA guidance, if a crossover study is carried out in two or more groups of subjects (e.g., if for logistical reasons only a limited number of subjects can be studied at one time), the statistical model should be modified to reflect the multi-group nature of the study. Hence we are planning to include ‘group effect' in our statistical model to evaluate whether the group effect is present or not.

We have worked out the following approaches for choosing a ‘group’, which we are mentioning below along with the probable concern that may occur by doing so.
Kindly suggest which is the most appropriate way for grouping of subject data among above approach and please also let us know if there is any other better option available beside those.


Edit: Category changed. [Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
23,654 posts in 4,992 threads, 1,570 registered users;
167 visitors (0 registered, 167 guests [including 25 identified bots]).
Forum time: 19:33 CEST (Europe/Vienna)

“Data! Data! Data!” he cried impatiently.
“I can’t make bricks without clay!”    Arthur Conan Doyle

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5